» Articles » PMID: 19036529

An Exploratory Study into the Role of Dynamic Contrast-enhanced Magnetic Resonance Imaging or Perfusion Computed Tomography for Detection of Intratumoral Hypoxia in Head-and-neck Cancer

Overview
Specialties Oncology
Radiology
Date 2008 Nov 28
PMID 19036529
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Hypoxia in patients with head-and-neck cancer (HNC) is well established and known to cause radiation resistance and treatment failure in the management of HNC. This study examines the role of parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and perfusion computed tomography (CT) as surrogate markers of intratumoral hypoxia, defined by using the exogenous marker of hypoxia pimonidazole and the endogenous marker carbonic anhydrase 9 (CA9).

Methods And Materials: Patients with HNC underwent preoperative DCE-MRI, perfusion CT, and pimonidazole infusion. Imaging parameters were correlated with pimonidazole and CA9 staining. The strength of correlations was tested by using a two-tailed Spearman's rank correlation coefficient.

Results: Twenty-three regions of interest were analyzed from the 7 patients who completed the DCE-MRI studies. A number of statistically significant correlations were seen between DCE-MRI parameters (volume transfer between blood plasma and extracellular extravascular space [EES], volume of EES, rate constant between EES and blood plasma, time at arrival of contrast inflow, time to peak, average gradient, and time to onset) and areas with a pimonidazole score of 4. In the case of CA9 staining, only a weak correlation was shown with wash-in rate. There were no significant correlations between perfusion CT parameters and pimonidazole staining or CA9 expression.

Conclusion: Intratumoral hypoxia in patients with HNC may be predicted by using DCE-MRI; however, perfusion CT requires further investigation.

Citing Articles

Translation of dynamic contrast-enhanced imaging onto a magnetic resonance-guided linear accelerator in patients with head and neck cancer.

Dubec M, Berks M, Price J, McDaid L, Gaffney J, Little R Phys Imaging Radiat Oncol. 2025; 33():100689.

PMID: 39802650 PMC: 11721217. DOI: 10.1016/j.phro.2024.100689.


The Prediction of Biological Features Using Magnetic Resonance Imaging in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

van der Hulst H, Jansen R, Vens C, Bos P, Schats W, de Jong M Cancers (Basel). 2023; 15(20).

PMID: 37894447 PMC: 10605807. DOI: 10.3390/cancers15205077.


Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel.

Romeo V, Stanzione A, Ugga L, Cuocolo R, Cocozza S, Quarantelli M Insights Imaging. 2022; 13(1):198.

PMID: 36528678 PMC: 9759606. DOI: 10.1186/s13244-022-01317-1.


The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Gallez B Front Pharmacol. 2022; 13:853568.

PMID: 35910347 PMC: 9335493. DOI: 10.3389/fphar.2022.853568.


Symptom burden and health-related quality of life six months after hyperbaric oxygen therapy in cancer survivors with pelvic radiation injuries.

Velure G, Muller B, Hauken M Support Care Cancer. 2022; 30(7):5703-5711.

PMID: 35320424 PMC: 9135809. DOI: 10.1007/s00520-022-06994-8.